EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Clearance of Midazolam and Metabolites during Continuous Renal Replacement Therapy in Critically Ill Patients with COVID-19

Tim J L Smeets, Hilde R H de Geus, Abraham J Valkenburg, Lauren Baidjoe, Diederik A M P J Gommers, Birgit C P Koch, Nicole G M Hunfeld, Henrik Endeman

Blood Purification · 2024

DOI: 10.1159/000534538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Purification, 2024. Verfasst von Tim J L Smeets und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Continuous Renal Replacement Therapy, COVID-19, Acute Kidney Injury. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Midazolam-based continuous intravenous sedation in patients admitted to the intensive care unit (ICU) was a necessity during the COVID-19 pandemic. However, benzodiazepine-based sedation is associated with a high incidence of benzodiazepine-related delirium and additional days on mechanical ventilation. Due to the requirement of high midazolam doses in combination with the impaired renal clearance (CL) of the pharmacological active metabolite 1-OH-midazolam-glucuronide (10% compared to midazolam), ICU patients with COVID-19 and continuous renal replacement therapy (CRRT) were at risk of unintended prolonged sedation. Several CRRT-related factors may have influenced the delivered CL of midazolam and its metabolites. Therefore, the aim of the study was to identify and describe these CRRT-related factors.

Methods

Pre-filter blood samples and ultrafiltrate samples were collected simultaneously. Midazolam, 1-OH-midazolam, and 1-OH-midazolam-glucuronide plasma samples were analyzed using an UPLC-MS/MS method. The prescribed CRRT dose was corrected for downtime and filter integrity using the urea ratio (urea concentration in effluent/urea concentration plasma). CL of midazolam and its metabolites were calculated with the delivered CRRT dose (corrected for downtime and saturation coefficient [SD]).

Results

Three patients on continuous venovenous hemodialysis (CVVHD) and 2 patients on continuous venovenous hemodiafiltration (CVVHDF) were included. Midazolam, 1-OH-midazolam, and 1-OH-midazolam-glucuronide concentrations were 2,849 (0–6,700) μg/L, 153 (0–295) μg/L, and 27,297 (1,727–39,000) μg/L, respectively. The SD was 0.03 (0.02–0.03) for midazolam, 0.05 (0.05–0.06) for 1-OH-midazolam, and 0.33 (0.23–0.43) for 1-OH-midazolam-glucuronide. The delivered CRRT CL was 1.4 (0–1.7) mL/min for midazolam, 2.7 (0–3.5) mL/min for 1-OH-midazolam, and 15.7 (4.0–27.7) mL/min for 1-OH-midazolam-glucuronide.

Conclusions

Midazolam and 1-OH-midazolam were not removed during CVVHD and CVVHDF. However, 1-OH-midazolam-glucuronide was removed reasonably, approximately up to 43%. CRRT modality, filter integrity, and downtime affect this removal. These data imply a personalized titration of midazolam in critically ill patients with renal failure and awareness for the additional sedative effects of its active metabolites.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Continuous Renal Replacement TherapyCOVID-19Acute Kidney InjuryHumansMidazolamCritical IllnessChromatography, LiquidGlucuronidesPandemicsTandem Mass SpectrometryUreaRenal Replacement Therapy

Stichwörter der Autor:innen

Critically ill patientsDrug blood levelDrug elimination routesMidazolamRenal replacement therapy

Substanzen

MidazolamGlucuronidesUrea

Autor:innen und Institutionen

  • Department of Hospital Pharmacy, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Intensive Care Adults, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Anesthesiology and Intensive Care, Isala Hospital, Zwolle, The Netherlands.

Zitieren

APA

Smeets, T. J. L., de Geus, H. R. H., Valkenburg, A. J., Baidjoe, L., Gommers, D. A. M. P. J., Koch, B. C. P., Hunfeld, N. G. M., & Endeman, H. (2024). The Clearance of Midazolam and Metabolites during Continuous Renal Replacement Therapy in Critically Ill Patients with COVID-19. Blood Purification. https://doi.org/10.1159/000534538

Vancouver

Smeets TJL, de Geus HRH, Valkenburg AJ, Baidjoe L, Gommers DAMPJ, Koch BCP, et al. The Clearance of Midazolam and Metabolites during Continuous Renal Replacement Therapy in Critically Ill Patients with COVID-19. Blood Purification. 2024. doi:10.1159/000534538

BibTeX
@article{Smeets2024,
  author = {Smeets, Tim J L and de Geus, Hilde R H and Valkenburg, Abraham J and Baidjoe, Lauren and Gommers, Diederik A M P J and Koch, Birgit C P and Hunfeld, Nicole G M and Endeman, Henrik},
  title = {The Clearance of Midazolam and Metabolites during Continuous Renal Replacement Therapy in Critically Ill Patients with COVID-19},
  journal = {Blood Purification},
  year = {2024},
  doi = {10.1159/000534538}
}
Kostenlos starten →